A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 448 participants.
Also called NCT06542874
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 448 participants
- Sponsor
- Registry
-
NCT06542874
-
- Other papers using this trial's data
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Bulgaria, Croatia, Germany, Greece, Hungary, Japan, Poland, Romania, Slovakia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT06542874. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-07 (actual); primary completion 2025-10-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
- Condition
- Type 2 Diabetes (T2D)
- Intervention (Drug)
- NNC0487-0111 subcutanous
- Intervention (Drug)
- Placebo (NNC0487-0111 subcutanous)
- Intervention (Drug)
- NNC0487-0111 oral
- Intervention (Drug)
- Placebo (NNC0487-0111 oral)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06542874- Content hash
f86e9df47a47e18b089b49e456dc558850d875d62be4a52bf5593a97f462d6ab